Pyoderma Gangrenosum clinical trials

Explore recruiting pyoderma gangrenosum clinical trials.

Recruiting pyoderma gangrenosum studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pyoderma Gangrenosum trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

FREE-study; De-escalation of anti-TNF therapy in adolescents and young adults with IBD with tight faecal calprotectin and trough level monitoring

Belgium, Netherlands, Spain

Therapeutic use (Phase IV) EU CTIS Study details

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ADAPTIVE PHASE III TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF VILOBELIMAB IN THE TREATMENT OF ULCERATIVE PYODERMA GANGRENOSUM

Belgium, Hungary, Poland, Netherlands, France, Spain +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy

Germany, Poland, Norway, Austria, Belgium, Sweden +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A double-blind, placebo-controlled, randomized withdrawal study of canakinumab in pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Pyoderma Gangrenosum trials by city

Pyoderma Gangrenosum clinical trials

Recruiting pyoderma gangrenosum studies right now

Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Also recruiting in Europe

FREE-study; De-escalation of anti-TNF therapy in adolescents and young adults with IBD with tight faecal calprotectin and trough level monitoring

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ADAPTIVE PHASE III TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF VILOBELIMAB IN THE TREATMENT OF ULCERATIVE PYODERMA GANGRENOSUM

A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy

A double-blind, placebo-controlled, randomized withdrawal study of canakinumab in pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome

Pyoderma Gangrenosum trials by city

Other conditions